MNNG/HOS Cl #5 [R-1059-D] 细胞

MNNG/HOS Cl #5细胞系 、MNNG/HOS Cl #5 、MNNG/HOS Cl #5 细胞株、MNNG/HOS Cl #5 细胞、MNNG/HOS Cl #5  骨肉瘤细胞

Cell line name MNNG/HOS Cl #5

Synonyms MNNG/HOS; MNNG-HOS; HOS-MNNG; HOS/MNNG; MNNGHOS; MNNG-HOS (Cl#5); MNNG/HOS Clone F-5; MNNG; R-1059-D; TE85; Te85; TE-85; HOS-TE85; Hos TE-85; HOS TE 85; HOS TE85; HOS (TE85); HOS(TE85); HOS (TE85, Clone F5); MNNG-HOS (TE 85, clone F-5); TE-85 clone F-5; HOS-Te85; TE 85.T; TE 85 ClF-5; HOS-TE85 clone 5; TE-85 clone 5

Accession CVCL_0439

Secondary accession CVCL_3952

Resource Identification Initiative To cite this cell line use: MNNG/HOS Cl #5 (RRID:CVCL_0439)

Comments Part of: MD Anderson Cell Lines Project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

Population: Caucasian.

Doubling time: ~24 hours (PubMed=21519327).

Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: MNNG/HOSC1#5; CCRID=5301HUM-KCB16037YJ.

Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.

PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0

Clover J., Gowen M.

Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?

Bone 15:585-591(1994)

 

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4

Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Cancer Genet. Cytogenet. 140:145-152(2003)

 

PubMed=19787792; DOI=10.1002/gcc.20717

Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Genes Chromosomes Cancer 49:40-51(2010)

 

PubMed=21519327; DOI=10.1038/labinvest.2011.72

Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.

Lab. Invest. 91:1195-1205(2011)

 

PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335

Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.

Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

PLoS ONE 7:E48262-E48262(2012)

 

PubMed=24136885; DOI=10.1002/pbc.24801; PMCID=PMC4154381

Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J., Wang W.-L., Kleinerman E.S.

Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.

Pediatr. Blood Cancer 61:618-626(2014)

 

PubMed=26320182; DOI=10.18632/oncotarget.5177; PMCID=PMC4745740

Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C.

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.

Oncotarget 6:29469-29481(2015)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=29334376; DOI=10.1038/nm.4475; PMCID=PMC5803371

Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Nat. Med. 24:176-185(2018)